2024
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn W, Li Y, Singal A, Simonetto D, Díaz L, Idalsoaga F, Ayares G, Arnold J, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez-Cadiz C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Dunn N, Waleed M, Stefanescu H, Bumbu A, Horhat A, Attar B, Agrawal R, Cabezas J, Echavaría V, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Guerra-Salazar P, Skladaný L, Kubánek N, Prado V, Clemente-Sanchez A, Rincon D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Hudson D, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. Hepatology 2024, 80: 1196-1211. PMID: 38607809, DOI: 10.1097/hep.0000000000000883.Peer-Reviewed Original ResearchAlcohol-associated hepatitisValidation cohortArtificial intelligenceModified Glasgow scoreMaddrey's discriminant functionMortality rateGlobal cohort studyShort-term mortalityPost-test probabilityApproximate mortality ratesSteroid therapyGlasgow scoreAH patientsSteroid useTransplant indicationRetrospective studyDerivation cohortLaboratory valuesCohort studyClinical trialsGlobal cohortPrognostic modelScoring systemAI algorithmsCohortSerum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis
Yamazaki T, Kouno T, Hsu C, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Schnabl B. Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis. Hepatology 2024, 80: 403-417. PMID: 38377466, PMCID: PMC11268475, DOI: 10.1097/hep.0000000000000777.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderSevere AHAH patientsAhR activationMicrobiota-derived tryptophan metabolitesSurvival rateAssociated with high mortalityCumulative survival rateAssociated with survivalAryl hydrocarbon receptor activationMulticenter cohortFecal metabolomePrognostic markerTryptophan metabolitesReceptor activationAryl hydrocarbon receptorPatientsUse disorderAH cohortSerumHigher mortalityAhRHepatitisCohort
2023
O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY
Idalsoaga F, Díaz L, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Grawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, P N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY. Annals Of Hepatology 2023, 28: 101035. DOI: 10.1016/j.aohep.2023.101035.Peer-Reviewed Original ResearchCox regressionSevere AHCohort studyHigh mortalityAlcohol‐Associated HepatitisRetrospective cohort studyKaplan-Meier curvesShort-term mortalityGlobal cohort studyLille modelMultivariable analyzesCorticosteroid treatmentMELD scoreAH patientsSevere entitySerum bilirubinClinical variablesBetter prognosticationWorldwide cohortSevere diseasePatientsDay 7Predicting ResponseDay 4Corticosteroids
2022
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Ventura-Cots M, Argemi J, Jones PD, Lackner C, Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carrillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet A, Lozano JJ, Lucey MR, Masson S, Mathurin P, Mendez-Sanchez N, Miquel R, Moreno C, Mounajjed T, Odena G, Kim W, Sancho-Bru P, Sands R, Szafranska J, Verset L, Schnabl B, Sempoux C, Shah V, Shawcross DL, Stauber RE, Straub BK, Verna E, Tiniakos D, Trépo E, Vargas V, Villanueva C, Woosley JT, Ziol M, Mueller S, Stärkel P, Bataller R. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut 2022, 71: 1856-1866. PMID: 34992134, PMCID: PMC11034788, DOI: 10.1136/gutjnl-2021-324295.Peer-Reviewed Original ResearchConceptsAlcohol-related liver diseaseAlcohol-related hepatitisAH patientsLiver diseaseAlcohol intakeDuctular reactionGamma-glutamyl transferase levelsProfound liver failureSevere neutrophil infiltrationWorse liver functionObservational multicentre studyOne-year mortalityBile acid metabolismMallory-Denk bodiesRNA microarray analysisNeutrophil infiltrationProspective cohortRetrospective cohortAdvanced fibrosisLiver failureMulticentre studySteatosis gradeLiver functionPericellular fibrosisSevere fibrosis